Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Oct 13;8(2):162–168. doi: 10.1002/sctm.18-0103

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors stem cells translational medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

(A): quantification of in vitro ECFC culture to reach confluency. Treatment of ECFC with C/S (red) significantly increase confluency rate compared to ethanol controls (black) (*p < .05; **p < .01). (B): assessment of cell cycle under flow cytometry showed significantly fewer ECFC in G0/1 phase and significantly more ECFC in S + G2M phase when treated with C/S (**p < .01). (C): quantification of tube formation in Matrigel with or without C/S (*p < .05; ***p < .001). (D): quantification of HPP colonies and LPP ECFC colonies with or without C/S (**p < .01). (E): assessment of long‐term passaging of ECFC with or without C/S (***p < .001). All error bars represented as standard deviation. Abbreviations: C/S, cyclosporine; ECFC, endothelial colony forming cells; HPP, high‐proliferative potential; LPP, low‐proliferative potential.